GLP-1 Drugs May Slow Liver Scarring in Patients With Fatty Liver Disease and Type 2 Diabetes
In a retrospective cohort of 242 patients with fatty liver disease and T2DM, GLP-1 RA users showed less liver fibrosis progression compared to non-users based on FIB-4 scores, though differences were small.
Quick Facts
What This Study Found
Patients treated with GLP-1 RAs showed less liver fibrosis progression (by FIB-4 score) compared to untreated controls in a retrospective cohort of 242 T2DM patients with steatotic liver disease, though differences were modest.
Key Numbers
Retrospective study period: January to December 2021. Compared GLP-1 RA users to non-users among patients with T2DM and NAFLD/NAFL/NASH.
How They Did This
Retrospective cohort study of adult patients with T2DM and NAFLD/NAFL/NASH (Jan-Dec 2021). Excluded: hepatitis B/C, pioglitazone use. 79 GLP-1 RA users compared to 163 controls. Primary outcome: change in FIB-4 score. Secondary: NAFLD Fibrosis Score (NFS). Follow-up labs 3-15 months after baseline.
Why This Research Matters
Fatty liver disease affects roughly 25% of the global population and is even more common in diabetes. Few approved treatments exist for liver fibrosis. If GLP-1 drugs — already widely used for diabetes — also slow liver scarring, it provides a compelling additional reason to choose them as first-line diabetes therapy in patients with fatty liver disease.
The Bigger Picture
GLP-1 drugs are emerging as potential therapies for liver disease in addition to diabetes and obesity. The recent approval of resmetirom for NASH and ongoing trials of semaglutide for liver fibrosis reflect growing interest in this area. This retrospective study adds real-world supporting evidence, though the definitive answers will come from randomized trials like the ongoing ESSENCE trial of semaglutide for NASH.
What This Study Doesn't Tell Us
Retrospective, non-randomized design — patients who received GLP-1 RAs may differ systematically from controls. Small sample size and short follow-up (3-15 months). FIB-4 is an indirect surrogate for fibrosis, not direct liver biopsy measurement. The baseline GLP-1 RA group had higher NFS, suggesting potentially more advanced disease. Confounding by other medications, lifestyle changes, and weight loss not fully controlled.
Questions This Raises
- ?Will randomized trials like ESSENCE confirm that semaglutide slows liver fibrosis in NASH patients?
- ?Is the protective effect driven by weight loss, improved insulin resistance, or direct hepatoprotective GLP-1R signaling?
- ?Should GLP-1 drugs be preferred over other diabetes medications in patients with concurrent fatty liver disease?
Trust & Context
- Key Stat:
- 32.6% on GLP-1 RA showed less fibrosis progression 79 of 242 patients with fatty liver disease and T2DM were taking GLP-1 drugs, and they showed less liver scarring progression compared to the 163 untreated controls
- Evidence Grade:
- Preliminary evidence from a retrospective cohort study with inherent confounding and small effect sizes. Supports the hypothesis but cannot establish causation. Randomized trials are needed.
- Study Age:
- Published in 2024, contributing to the rapidly growing evidence base for GLP-1 drugs in liver disease ahead of results from definitive randomized trials.
- Original Title:
- Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study.
- Published In:
- Journal of pharmacy practice, 37(6), 1297-1302 (2024)
- Authors:
- Wood, Marci, Kennedy, Amanda G(2), Khan, Sidra, Hitt, Juvena R, Davis, Kayla, Reddy, Sheela S, Gilbert, Matthew P
- Database ID:
- RPEP-09534
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs actually treat fatty liver disease?
The evidence is building but not yet definitive. This retrospective study suggests GLP-1 drug users have less liver fibrosis progression, and several clinical trials are testing this formally. The ESSENCE trial is specifically studying semaglutide for NASH (the inflammatory form of fatty liver). GLP-1 drugs likely help through multiple mechanisms: weight loss, improved insulin resistance, and possibly direct anti-inflammatory effects on the liver. But they're not yet approved for liver disease.
What is the FIB-4 score?
FIB-4 is a simple calculation using your age, platelet count, and liver enzyme levels (AST, ALT) to estimate liver fibrosis (scarring). A lower score suggests less fibrosis. It's not as accurate as a liver biopsy, but it's non-invasive and can be calculated from routine blood tests, making it useful for tracking changes over time in large patient groups.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09534APA
Wood, Marci; Kennedy, Amanda G; Khan, Sidra; Hitt, Juvena R; Davis, Kayla; Reddy, Sheela S; Gilbert, Matthew P. (2024). Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study.. Journal of pharmacy practice, 37(6), 1297-1302. https://doi.org/10.1177/08971900241253661
MLA
Wood, Marci, et al. "Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study.." Journal of pharmacy practice, 2024. https://doi.org/10.1177/08971900241253661
RethinkPeptides
RethinkPeptides Research Database. "Impact of GLP-1 Receptor Agonist Use in Patients With Steato..." RPEP-09534. Retrieved from https://rethinkpeptides.com/research/wood-2024-impact-of-glp1-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.